Search Results - "Weigel, Marion T"

Current and emerging biomarkers in breast cancer: prognosis and prediction by Weigel, Marion T, Dowsett, Mitch

“…Breast cancer treatment has experienced several changes in the past decades due to the discovery of specific prognostic and predictive biomarkers that enable…”
Get full text

Differential expression of MMP-2, MMP-9 and PCNA in endometriosis and endometrial carcinoma by Weigel, Marion T, Krämer, Julia, Schem, Christian, Wenners, Antonia, Alkatout, Ibrahim, Jonat, Walter, Maass, Nicolai, Mundhenke, Christoph

“…Abstract Objectives Endometriosis is a common gynaecological disease with clinical symptoms such as chronic pain, infertility and intra-abdominal adhesions…”
Get full text

In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells by Weigel, Marion T, Dahmke, Linda, Schem, Christian, Bauerschlag, Dirk O, Weber, Katrin, Niehoff, Peter, Bauer, Maret, Strauss, Alexander, Jonat, Walter, Maass, Nicolai, Mundhenke, Christoph

“…Breast cancer treatment is based on a combination of adjuvant chemotherapy followed by radiotherapy effecting intracellular signal transduction. With the…”
Get full text

Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer by Weigel, Marion T, Ghazoui, Zara, Dunbier, Anita, Pancholi, Sunil, Dowsett, Mitch, Martin, Lesley-Ann

“…The majority of breast tumors at primary diagnosis are estrogen receptor positive (ER+). Estrogen (E) mediates its effects by binding to the ER. Therapies…”
Get full text

Hysterectomy trends over a 9-year period in an endoscopic teaching center by Schollmeyer, Thoralf, Elessawy, Mohamed, Chastamouratidhs, Babis, Alkatout, Ibrahim, Meinhold-Heerlein, Ivo, Mettler, Liselotte, Jonat, Walter, Weigel, Marion T

“…Abstract Objective To investigate trends in the performance of hysterectomy at a single certified endoscopic teaching center. Methods Data were collected…”
Get full text

Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment by Weigel, Marion T, Rath, Katrin, Alkatout, Ibrahim, Wenners, Antonia S, Schem, Christian, Maass, Nicolai, Jonat, Walter, Mundhenke, Christoph

“…Nilotinib is a selective tyrosine kinase inhibitor of c-Kit, Abl and platelet-derived growth factor receptor-α/β. To evaluate nilotinib's potential use as a…”
Get more information

Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles by Bauerschlag, Dirk O, Ammerpohl, Ole, Bräutigam, Karen, Schem, Christian, Lin, Qiong, Weigel, Marion T, Hilpert, Felix, Arnold, Norbert, Maass, Nicolai, Meinhold-Heerlein, Ivo, Wagner, Wolfgang

“…Many patients with ovarian cancer disease relapse within 6 months after adjuvant chemotherapy, with a limited prognosis. Epigenetic modifications have been…”
Get more information

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo by Martin, Lesley-Ann, Pancholi, Sunil, Farmer, Ian, Guest, Stephanie, Ribas, Ricardo, Weigel, Marion T, Thornhill, Allan M, Ghazoui, Zara, A'Hern, Roger, Evans, Dean B, Lane, Heidi A, Johnston, Stephen R, Dowsett, Mitch

“…Strategies to improve the efficacy of endocrine agents in breast cancer (BC) therapy and to delay the onset of resistance include concomitant targeting of the…”
Get full text

Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer by Martin, Lesley-Ann, Davies, Giles L. S, Weigel, Marion T, Betambeau, Nadine, Hills, Margaret J, Salter, Janine, Walsh, Geraldine, A'Hern, Roger, Dowsett, Mitch

“…Cyclo-oxygenase 2 (COX-2) is implicated in the regulation of aromatase transcription in malignant breast tissue and has been considered as a potential target…”
Get full text

Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR β signalling by Weigel, Marion T, Meinhold-Heerlein, Ivo, Bauerschlag, Dirk O, Schem, Christian, Bauer, Maret, Jonat, Walter, Maass, Nicolai, Mundhenke, Christoph

“…Abstract Introduction Imatinib mesylate is a tyrosine kinase receptor inhibitor targeted against PDGFR α and β, c-kit and bcr-abl. These receptors regulate…”
Get full text

Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer by Maass, Nicolai, Schem, Christian, Bauerschlag, Dirk O, Tiemann, Katharina, Schaefer, Fritz W, Hanson, Sven, Muth, Mathias, Baier, Monika, Weigel, Marion T, Wenners, Antonia S, Alkatout, Ibrahim, Bauer, Maret, Jonat, Walter, Mundhenke, Christoph

“…Imatinib is a tyrosine kinase inhibitor of BCR-ABL, ABL, PDGFR-α and -β, KIT, and DDR. In solid tumors, it inhibits proliferation and invasiveness and…”
Get more information

Sunitinib (SU11248) Inhibits Growth of Human Ovarian Cancer in Xenografted Mice by BAUERSCHLAG, Dirk O, SCHEM, Christian, TIWARI, Sanjay, EGBERTS, Jan H, WEIGEL, Marion T, KALTHOFF, Holger, JONAT, Walter, MAASS, Nicolai, MEINHOLD-HEERLEIN, Ivo

“…Treatment of ovarian cancer is still challenging especially in recurrent platinum refractory cases. Sunitinib is a multi tyrosine kinase inhibitor targeting…”
Get full text

role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer by Bauerschlag, Dirk O, Schem, Christian, Weigel, Marion T, von Kaisenberg, Constantin, Strauss, Alexander, Bauknecht, Thomas, Maass, Nicolai, Meinhold-Heerlein, Ivo

“…Introduction In advanced ovarian cancers (OCs), p53 mutations are frequently observed. The objective of this study was to explore the value of the p53…”
Get full text

Clinical and safety data of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer (MBC) by Mundhenke, Christoph, Schem, Christian, Bauerschlag, Dirk Olaf, Weigel, Marion T., Wenners, Antonia Sophie, Schaefer, Fritz Werner, Tiemann, Katharina, Hanson, Sven, Muth, Mathias, May, Christoph, Jonat, Walter, Maass, Nicolai

“…Abstract only e13503 Background: Imatinib is a tyrosine kinase inhibitor of bcr-abl, PDGF-R, SCF, c-Kit and abl. In solid tumors it inhibits proliferation and…”
Get full text

Abstract 4598: Temporal changes of gene expression in breast cancer cells during adaptation to estrogen deprivation highlight the clinical potential for targeting kinase pathways by Ghazoui, Zara, Weigel, Marion T., Anderson, Helen, Dunbier, Anita, Dowsett, Mitch, Martin, Lesley-Ann

“…Aromatase inhibitors (AI) have improved the treatment of estrogen receptor positive (ER+) early and advanced breast cancer (BC). However, the efficacy of AIs…”
Get full text

Abstract 2920: Experimental and clinical studies reveal the PDGF/Abl pathway as a novel therapeutic target in endocrine-resistant breast cancer by Weigel, Marion T., Ghazoui, Zara, Lykkesfeldt, Anne E., Anderson, Helen, Dunbier, Anita, Mundhenke, Christoph, Dowsett, Mitch, Martin, Lesley-Ann

“…The majority of breast tumours at primary diagnosis are estrogen receptor positive (ER). Estrogen (E) mediates its effects by binding to the ER. E-bound ER…”
Get full text

Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR [beta] signalling by Weigel, Marion T, Meinhold-Heerlein, Ivo, Bauerschlag, Dirk O, Schem, Christian, Bauer, Maret, Jonat, Walter, Maass, Nicolai, Mundhenke, Christoph

“…Introduction Imatinib mesylate is a tyrosine kinase receptor inhibitor targeted against PDGFR α and β, c-kit and bcr-abl. These receptors regulate cellular…”
Get full text